Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Epistemonikos ID: c34dc72657f99fc3d4f0a52a988199ba5ef35a1e
First added on: May 13, 2024